Insulet (PODD) Scheduled to Post Quarterly Earnings on Thursday

Insulet (NASDAQ:PODD) will release its earnings data after the market closes on Thursday, May 9th. Analysts expect Insulet to post earnings of $0.39 per share for the quarter. Insulet has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Parties interested in registering for the company’s conference call can do so using this link.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.73. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The business had revenue of $509.80 million for the quarter, compared to analyst estimates of $461.26 million. During the same quarter in the previous year, the company posted $0.55 EPS. Insulet’s quarterly revenue was up 37.9% compared to the same quarter last year. On average, analysts expect Insulet to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Insulet Price Performance

Shares of PODD opened at $170.27 on Thursday. The business has a 50-day moving average of $170.69 and a 200-day moving average of $180.53. Insulet has a 1 year low of $125.82 and a 1 year high of $335.91. The company has a market capitalization of $11.92 billion, a price-to-earnings ratio of 58.51, a price-to-earnings-growth ratio of 3.07 and a beta of 0.98. The company has a debt-to-equity ratio of 1.86, a current ratio of 3.51 and a quick ratio of 2.62.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. JPMorgan Chase & Co. increased their price target on Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Piper Sandler decreased their price target on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research note on Friday, February 23rd. Stifel Nicolaus increased their price target on Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a report on Monday, February 5th. Finally, Barclays decreased their price objective on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a report on Monday, February 26th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $243.21.

Insider Transactions at Insulet

In related news, Director Shacey Petrovic sold 11,609 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the sale, the director now owns 2,567 shares in the company, valued at $418,215.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.90% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.